Correlation Between SAB Biotherapeutics and Pluri

Can any of the company-specific risk be diversified away by investing in both SAB Biotherapeutics and Pluri at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining SAB Biotherapeutics and Pluri into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between SAB Biotherapeutics and Pluri Inc, you can compare the effects of market volatilities on SAB Biotherapeutics and Pluri and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in SAB Biotherapeutics with a short position of Pluri. Check out your portfolio center. Please also check ongoing floating volatility patterns of SAB Biotherapeutics and Pluri.

Diversification Opportunities for SAB Biotherapeutics and Pluri

0.21

Correlation Coefficient

SAB Biotherapeutics  Pluri

Modest diversification

The 3 months correlation between SAB and Pluri is 0.21. Overlapping area represents the amount of risk that can be diversified away by holding SAB Biotherapeutics and Pluri Inc in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Pluri Inc and SAB Biotherapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on SAB Biotherapeutics are associated (or correlated) with Pluri. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Pluri Inc has no effect on the direction of SAB Biotherapeutics i.e., SAB Biotherapeutics and Pluri go up and down completely randomly.

Pair Corralation between SAB Biotherapeutics and Pluri

Given the investment horizon of 90 days SAB Biotherapeutics is expected to under-perform the Pluri. But the stock apears to be less risky and, when comparing its historical volatility, SAB Biotherapeutics is 1.1 times less risky than Pluri. The stock trades about -0.04 of its potential returns per unit of risk. The Pluri Inc is currently generating about 0.05 of returns per unit of risk over similar time horizon. If you would invest  450.00  in Pluri Inc on February 3, 2025 and sell it today you would earn a total of  40.00  from holding Pluri Inc or generate 8.89% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

SAB Biotherapeutics  vs.  Pluri Inc

SAB Biotherapeutics

Risk-Adjusted Performance

Very Weak

Over the last 90 days SAB Biotherapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's fundamental drivers remain comparatively stable which may send shares a bit higher in June 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Pluri Inc

Risk-Adjusted Performance

Insignificant

Compared to the overall equity markets, risk-adjusted returns on investments in Pluri Inc are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. Even with relatively weak basic indicators, Pluri reported solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with SAB Biotherapeutics and Pluri

The main advantage of trading using opposite SAB Biotherapeutics and Pluri positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if SAB Biotherapeutics position performs unexpectedly, Pluri can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Pluri will offset losses from the drop in Pluri's long position.

The idea behind SAB Biotherapeutics and Pluri Inc pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.